App-Quantinova.ai

FACTORS ASSOCIATED WITH HYDROXYCHLOROQUINE USE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH END STAGE RENAL DISEASE

Maria Salgado Guerrero - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

Hydroxychloroquine

FREQUENCY OF HYDROXYCHLOROQUINE RETINOPATHY IN THE HOPKINS LUPUS COHORT

Michelle A Petri - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

Hydroxychloroquine

HYDROXYCHLOROQUINE BLOOD LEVELS PREDICT RETINOPATHY IN SLE

Michelle A. Petri - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertension

Hydroxychloroquine

HYDROXYCHLOROQUINE ON THE TOP OF STANDARD TREATMENT WITH LOW DOSE ASPIRIN AND LOW MOLECULAR WEIGHT HEPARIN SIGNIFICANTLY REDUCES THE PROBABILITY OF PREGNANCY MORBIDITY IN WOMEN WITH MULTIPLE POSITIVITY FOR ANTI-PHOSPHOLIPID ANTIBODIES

Cecilia Chighizola - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Spontaneous preterm delivery

Hydroxychloroquine

HYDROXYCHLOROQUINE SIGNIFICANTLY REDUCES SERUM MARKERS OF ENDOTHELIAL INJURY AND NEMO VIDEOCAPILLAROSCOPY SCORE IN SYSTEMIC SCLEROSIS: A 3-MONTHS PROSPECTIVE OBSERVATIONAL STUDY

Fabio Basta - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

Hydroxychloroquine

HYDROXYCHLOROQUINE DOSING IN PATIENTS WITH RHEUMATIC DISEASE ACROSS THE U.S.: DATA FROM THE RHEUMATOLOGY INFORMATICS SYSTEM FOR EFFECTIVENESS (RISE) REGISTRY

Zara Izadi - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

HYDROXYCHLOROQUINE FOR THE PREVENTION OF RELAPSES IN A SERIES OF 812 PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME: THE HIBISCUS RETROSPECTIVE STUDY

Cristina Belizna - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Hydroxychloroquine

IMPLEMENTATION OF HYDROXYCHLOROQUINE AT THE PRE-CONCEPTIONAL STAGE IN THE TREATMENT OF ANTIPHOSPOLIPID SYNDROME ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Dmitrii Bublikov - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

MORTALITY OVER UP TO 14 YEARS FOLLOW-UP IN MTX-REFRACTORY PATIENTS RANDOMIZED TO A STRATEGY STARTING WITH ADDITION OF INFLIXIMAB OR ADDITION OF SULFASALAZINE AND HYDROXYCHLOROQUINE

Heather Miller - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

PCSK9 IN ATHEROSCLEROTIC INFLAMMATION OF LUPUS PATIENTS AND MURINE MODEL OF LUPUS WITH ATHEROSCLEROSIS

Chenglong Fang - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Hydroxychloroquine

PREGNANCY IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: MATERNAL AND FETAL COMPLICATIONS

Tatiana Kirsanova - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus

Hydroxychloroquine

PREGNANCY OUTCOME IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH HYDROXYCHLOROQUINE: 10 YEARS EXPERIENCE

Kyaw Min Tun - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

QUALITY IMPROVEMENT IN PEDIATRIC RHEUMATOLOGY: A NEW APPROACH TO CARE IN QATAR

Sharon Bout-Tabaku - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Rheumatoid arthritis

Hydroxychloroquine

REVIEW OF HYDROXYCHLOROQUINE USE AND DEVELOPMENT OF A REGIONAL STRATEGY TO MINIMISE RETINAL TOXICITY

Ursula Laverty - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

RISK OF CORONARY ARTERY DISEASE AND STROKE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS USING JAPANESE HEALTH INSURANCE DATABASE

Ryoko Sakai - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Lupus

Hydroxychloroquine

THE ADDITIVE EFFECTS OF HYDROXYCHLOROQUINE TO MAINTENANCE THERAPY WITH STANDARD OF CARE IN PATIENTS WITH SYSTEMIC LUPUS: ERYTHEMATOSUS

Ippei Miyagawa - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

TREATMENT OF INFLAMMATORY MYOSITIS IN CLINICAL PRACTICE: ANALYSIS OF THE REGISTRY OF INFLAMMATORY MYOSITIS FROM THE MADRID COMMUNITY (REMICAM)

Beatriz Joven-Ibez - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Myositis

Hydroxychloroquine

USE OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: THE RELATIONSHIP OF IMMUNOGENICITY WITH THERAPY

Galina Tarasova - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

WHOLE BLOOD VERSUS SERUM HYDROXYCHLOROQUINE LEVELS FOR DRUG MONITORING OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PRELIMINARY RESULTS OF A PHARMACOLOGICAL STUDY

Benoit Blanchet - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Association of SMAD4 loss with response to neoadjuvant chemotherapy with the autophagy inhibitor hydroxychloroquine in patients with pancreatic adenocarcinoma.

Naomi Fei - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

Hydroxychloroquine

Filters

1151 Abstracts